# 99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer

> **NCT05622240** · EARLY_PHASE1 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 99mTc-MIRC213

## Key facts

- **NCT ID:** NCT05622240
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-07
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622240, "99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05622240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*